Who is sponsoring NCT02426294?

NCT02426294 is sponsored by Pusan National University Hospital.

What condition does NCT02426294 study?

NCT02426294 studies Type 2 Diabetes Mellitus.

What drugs are being tested in NCT02426294?

Interventions: Pioglitazone, Glimepiride.

What is the status of NCT02426294?

NCT02426294 is currently UNKNOWN.

Last reviewed 2015-04-21 · How we verify

A Phase IV, Multicenter, Randomized, Active Comparator Controlled Study of the Addition of Pioglitazone Compared With Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Alogliptin

NCT02426294 Phase 4 UNKNOWN

The purpose of this study is to compare the treatment effect at week 26 between the two groups, sulfonylurea (SU, glimepiride) administration and thiazolidinedione (TZD, Pioglitazone) administration, as the third-order drug among patients whose treatment is not sufficient after the combined administration of Metformin and Alogliptin.

Details

Lead sponsor	Pusan National University Hospital
Phase	Phase 4
Status	UNKNOWN
Enrolment	154
Start date	2015-02
Completion	2016-05

Conditions

Type 2 Diabetes Mellitus

Interventions

Pioglitazone
Glimepiride

Primary outcomes

Evidence of efficacy of glycemic control indicated by the mean changes of HbA1c (%) at week 26 from baseline — 26 weeks

Countries

South Korea